CERo Therapeutics’ Novel Chimeric Engulfment Receptor T Cells Exhibit Multifunctional Properties and Enhanced Tumor Killing

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CERo Therapeutics presents preclinical data at SITC 2021 characterizing novel chimeric engulfment receptor (CER) T cells.

Click to view original post